News, Links and Commentary
Sunday, July 02, 2006
Lucentis Approved by FDA for Treatment of Wet MD
Genentech's anti-angiogenesis drug Lucentis is approved by the US Food and Drug Administration (FDA).
'FDA Approves New Biologic Treatment for Wet Age-Related Macular Degeneration', FDA media release, 30 June 2006.
The Food and Drug Administration (FDA) today approved Lucentis (ranibizumab injection) for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD). Lucentis is the first treatment which, when dosed monthly, can maintain the vision of more than 90 percent of patients with this type of AMD. Lucentis is a new molecular entity (NME), meaning it contains an active substance that has never before been approved for marketing in any form in the United States.
'FDA Approves New Biologic Treatment for Wet Age-Related Macular Degeneration', FDA media release, 30 June 2006.
Comments:
Post a Comment
